Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics-Reference-Cited by-同舟云学术

Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics

Published:2021-11-02 Issue:11 Volume:30 Page:1141-1157
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Barrera-Chimal Jonatan¹²,Kolkhof Peter³,Lima-Posada Ixchel⁴,Alexandre Joachim⁵,Rossignol Patrick⁶,Jaisser Frederic⁴⁶^ORCID

Affiliation:

1. Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico

2. Unidad de Investigación UNAM-INC, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

3. Heart and Vascular Diseases, R&D Preclinical Research, Bayer AG, Germany

4. Centre de Recherche Des Cordeliers, Sorbonne Université, Université de Paris, Paris, France

5. Normandy University, University of Caen Normandy, Centre Hospitalier Universitaire (CHU) de Caen Normandie, Department of Pharmacology, Ea 4650, Signalisation, Électrophysiologie Et Imagerie Des Lésions d’Ischémie-Reperfusion Myocardique, Caen, France

6. Université de Lorraine, Inserm, Centre d’Investigations Cliniques Plurithématique - 1433, and Inserm U1116; Chru Nancy; F-crin Ini-crct, Nancy, France

Funder

This work was supported by INSERM (Jonatan Barrera-Chimal, Ixchel Lima-Posada, Patrick Rossignol

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2021.2002844

Reference80 articles.

1. The Multifaceted Mineralocorticoid Receptor

2. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure

3. Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases